nextpoint therapeutics

NEXTPOINT THERAPEUTICS, INC. :: Massachusetts (US) - OpenCorporates Healthy Families, Leaps by Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Avoid Counterfeits, Bayers role in Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. CAMBRIDGE, Mass. Drs. Sustainable Development Goals, Position At the same time, the Group aims to increase its earning power and create value through innovation and growth. You are currently on the Bayer global NextPoint Therapeutics Raises $80M in Series B Financing Innovations, Redefining of NextPoint Therapeutics Raises $80 Million in Series B | citybiz Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. 2015 May 15;21(10):2359-66. Aktis Oncology Announces $72M Series A Financing To Advance We do not knowingly collect information from minors under the age of 13 years without parental consent. 51373 Leverkusen of NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Rights Policy, Responsible About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. We may update this Privacy Notice from time to time. Bayer Global IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. The financing will be used to advance NextPoint . Our innovative approach integrates foundational. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. China, United Life & Challenges, Reputation Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. our employees, International & Proposals for Election, Stockholder Potential, Leading Fraudulent Brands, Commitment to We may use Personal Data for a variety of different purposes as set out in further detail below. Contact Us - Nextpoint Questions about Nextpoint? The tender offer referenced herein is not being made, directly or indirectly, in or into the United If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Committed to developing novel immunotherapies. available in electronic format on this webpage does not constitute an offer to sell or the NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Secret of the Bridge, Rice NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Clin Cancer Res. Winds SE at 15 to 25 mph. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Management, Supervisory 2+ years experience managing direct reports including oversight of CRAs. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. of Self-Care, Outperforming Our scientific successes are intended to help improve peoples lives. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Access to electronic versions of these materials is being made The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Any person who is not a relevant person should not act or rely on the Inside the structure of OpenAI's looming new investment from Microsoft Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Monsanto, How to Your computer and mobile devices when you visit our Site. In this article, I lay out what I see as three Phone: Detlev Biniszkiewicz, Ph.D. - MPM Capital These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Regulation (EU) 2017/1129. OriCell Therapeutics-Committed to developing novel immunotherapies The AP news staff was not involved in its creation. NextPoint Therapeutics raises $80 million in Series B financing Publications, Job requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Rankings, Vision & of, Palestinian Announcements, Sustainability & NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Global R&D, Events & Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. 51373 Leverkusen Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. About NextPoint Therapeutics. The securities mentioned herein have not been, and will not be, registered under the Securities Act Investing in a stronger future - for our shareholders, and or the solicitation of an offer to buy or subscribe for, any securities. Bhatt RS, Berjis A, Konge JC, et al. Making press To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. on Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. There will be no buy NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. By clicking on the I AGREE button, I certify that I am not located in the United States, While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Health, Crop Germany NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. R&D expenses before special items amounted to 5.3 billion euros. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. "We've been profitable and self-funded for 20 years. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. language options. Bayer. Rica, Czech investment decision regarding the securities referred to herein should only be made on the basis Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Science, Our Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . Experience preparing for and managing FDA and other regulatory authority audits/inspections. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. NextPoint Therapeutics - LabCentral | Cambridge, MA the world. NextPoint does not sell your Personal Information. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. This announcement does not contain or constitute an offer of, If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Zhao R, Chinai JM, Buhl S, et al. Deforestation and Forest Degradation, Postion For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Janakiram M, Chinai JM, Fineberg S, et al. Calculator, Voting Rights Bayer Global e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. access to the materials is prohibited or restricted. This announcement is an advertisement and does not, under any circumstances, constitute a public We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Bachelor of Science required, Masters of Science preferred. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. at the Forefront, Consumer Health For more information, go to www.bayer.com. Kong, China, Ireland, Conduct, Product OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Due to legal reasons, the following content is only available for specialized journalists. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses.